Tevogen Bio Holdings Inc. (TVGNW)
- Previous Close
0.0499 - Open
0.0569 - Bid --
- Ask --
- Day's Range
0.0454 - 0.0569 - 52 Week Range
0.0454 - 0.0569 - Volume
81,563 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) -0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in 2020 and is headquartered in Warren, New Jersey.
tevogen.comRecent News: TVGNW
View More
Compare To: TVGNW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TVGNW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-746.67%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.27M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
1.28M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
9.82M